Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin ...
FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race ...
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a "designated news release" for the purposes of ...
Revolution Medicines recently secured FDA clearance for an expanded access program for its investigational pancreatic cancer drug daraxonrasib, following Phase 3 trial data showing a statistically ...
Eligible patients in the expanded access program will be able to receive daraxonrasib from their healthcare provider ...
“Let it grow, let it blossom,” said Eric Clapton, and so the Food and Drug Administration expects of expanded access programs with the issuance of its guidance on “Expanded Access to Investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results